Premium
Low dose cytosine arabinoside in the treatment of acute non‐lymphocytic leukaemia
Author(s) -
Jensen Mogens Krogh,
Ahlbom Göran
Publication year - 1985
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1985.tb02789.x
Subject(s) - cytosine , medicine , cytarabine , leukemia , gastroenterology , toxicity , complete remission , chemotherapy , biology , genetics , dna
Complete remissions were obtained with low dose cytosine arabinoside (ARA‐C) in 8 of 21 previously untreated patients with ANLL above 60 years of age and in 2 of 4 previously treated patients below 60 years of age. 7 of the patients remain in remission after 1–26 months. The results demonstrate that low dose ARA‐C with rather low toxicity may induce remissions in elderly patients with ANLL.